Short-acting beta agonists

Cho SH, Oh SY, Bahn JW, et al. (2005) Association between bronchodUating response to short-acting beta-agonist and non-synonymous single-nucleotide polymorphisms of beta-adrenoceptor gene. Clin Exp Allergy. 35, 1162-1167. 

Typically, a mean improvement of 701/min would be seen following treatment with a short acting beta-agonist and A was chosen to be about 20 per cent of this. 

Wraight JM, Smith AD, Cowan JO, et al. Adverse effects of short-acting beta-agonists potential impact when anti-inflammatory therapy is inadequate. Respirology. 2004 9 215-221. 

A. Short-acting beta-agonist bronchodUators—e.g., salbutamol (albuterol in tbe United States), terbutaline, fenoterol... 

Adjunctive pharmacological therapies, aimed primarily at the cardio-respiratory system, will have a modest role initially, but as the disease becomes more chronic, there is a reduction in the potential for medications to contribute substantially. Therefore, although medications are prescribed in an attempt to optimize performance, it is important to do so in a way that minimizes the possibility of detrimental effects that can occur, for example, from corticosteroids or short-acting beta agonists. The following comments highlight some of the adjunctive therapies for the ventilated patient. 

Q12 It is recommended that a trial of a short-acting beta-2-agonist (/S)-agonist) inhaler be made for a few weeks as some COPD patients do benefit from bronchodilation. Although his doctor has prescribed a bronchodilator previously, it may be useful for Bill to try this again. There should also be a trial of a corticosteroid inhaler, as this diminishes the inflammatory component of COPD. If there is no appreciable benefit after four weeks, the steroid should be discontinued. 

Reverse transcriptase polymerase chain reaction Short-acting beta-adrenoceptor agonist Standardized mortality rate Single nucleotide polymorphism Serotonin and noradrenaline reuptake inhibitor Selective serotonin reuptake inhibitor Simian virus 40... 

Exercise-induced bronchoconstriction Do not use montelukast as monotherapy. Patients should continue to use their usual regimen of inhaled beta-agonists as prophylaxis and have a short-acting inhaled beta-agonist available for rescue. 

Q1 The most commonly used reliever in asthma therapy is a short-acting bronchodilator, such as the beta-2-agonists (/ -agonists) salbutamol or terbutaline. These are safe and effective agents for mild to moderate symptoms and are taken directly into the respiratory tract via an inhaler device. 

Beta-2-agonists /02-agonists) such as salbutamol (short-acting) or salmeterol (longer-acting) are effective bronchial muscle relaxants administered by inhalation. 

Beta-2 adrenoceptor agonists Inhaled Short-acting Bitolterol, Clenbuterol, Fenoterol, Levosalbutamol, Pirbuterol, Procaterol, Reproterol, Salbutamol (Albuterol), Terbutaline, Tolubuterol Long-acting Arformoterol, Formoterol, Salmeterol... 

In 24 children with major congenital malformations, there was no increased risk of malformations with gestational exposures to short- or long-acting beta-adrenoceptor agonists [54. ... 

---